UCDCCC NCTN UG1 PROGRAM

UCDCCC NCTN UG1 项目

• 批准号: 10584617
• 负责人: DAVID R GANDARA
• 金额: $ 49.49万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-06 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10584617
• 关键词: Area; Awareness; Biometry; California; Cancer Control; Clinical Research; Clinical Trials; Communities; Comprehensive Cancer Center; Ensure; Faculty; Genomics; Goals; Health; Human; Institution; Laboratories; Lead; Leadership; Link; Malignant Neoplasms; Medical Oncology; Molecular Biology; NCI-Designated Cancer Center; Nursing Research; Pathology; Persons; Population; Radiation Oncology; Radiology Specialty; Research Personnel; Research Support; Resources; Site; Structure; Surgical Specialties; Translational Research; Translations; biomedical referral center; cancer care; cancer prevention; career development; design; experience; improved; innovation; medical specialties; minority patient; multidisciplinary; patient population; programs; rural patients; rural underserved; tumor

PROJECT SUMMARY/ABSTRACT As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer care to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this application as a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD, UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the NCTN group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to NCI-sponsored clinical trials activities, as well as to NCI-related steering committees and initiatives. This UG1 effort is anticipated to increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. With an already strong track record in translational and clinical research leadership for NCTN, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for clinical trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials “hub” for accrual to NCI-sponsored studies throughout North-Central California, this NCTN UG1 initiative creates a additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will be impactful and ensure robust accrual to NCTN trials.

项目摘要/摘要 作为北加州内陆约600万人的唯一NCI指定的癌症中心， 加州大学戴维斯分校综合癌症中心（UCDCCC）既可以为大型和大型癌症护理 人口不断增长，并作为该地区的高等教育癌症护理中心。为了这 由DRS领导的NCTN网络领导学术参与站点的应用。大卫·R·甘达拉（David R Gandara），医学博士， Richard K Valicenti，医学博士，UCDCCC将利用已经建立的多学科癌症团队 医学肿瘤学，辐射肿瘤学，外科专科，分子​​生物学/基因组学的研究者， 病理学，放射学，生物统计学，护士和临床研究支持，以提供临床试验专业知识， NCTN研究的科学和行政领导和辅助，遍布广泛的肿瘤类型和 在整个NCTN组网络中。 UCDCCC及其教职员工拥有长期且可靠的往绩 对NCI赞助的临床试验活动以及与NCI相关的转向委员会的有影响力贡献 和倡议。预计这项UG1的努力将增加参与的范围和范围，包括 整合其他研究人员并为新教师和初级提供职业发展机会 调查人员。在NCTN的转化和临床研究领导中已经有很强的记录， UCDCCC被中毒以利用独特的机构优势作为临床试验的实验室资源 并有助于假设驱动的临床研究。 基于已有二十年的已经作为NCI赞助研究的临床试验“枢纽” 在整个加利福尼亚州中北部，这项NCTN UG1计划为UCDCCC创造了额外的机会 两者都提高了主要站点的准确性，并通过UCDCCC将对NCTN试验的访问扩展到社区 癌症护理网络和会员网站，包括大量服务不足，粗糙和少数患者 人群。总之，UCDCCC代表跨学科的组织和领导结构 与临床试验计划相关联，该计划将有影响力，并确保NCTN试验的良好准确性。